

Jared Rolfe
Bridgton
LD 1567

LD 1567: Ought to Pass

LD 1567 ensures consumer transparency by requiring labeling for cannabis products treated with irradiation or ozone, a critical protection for both adult-use and medical users. As a consumer, I have the right to know if my cannabis product was irradiated or treated with ozone, just as FDA regulations require labeling for irradiated food. Labeling ensures consumers can avoid treated products that may pose health risks or alter efficacy.

Research shows irradiation reduces terpenes—compounds critical to cannabis’s aroma and effects—by an average of 17%, diminishing the medical benefits patients seek for conditions like chronic pain. Reduced terpenes impair cannabis’s effectiveness, harming medical patients who rely on specific strains.

This labeling requirement should also apply to the medical cannabis program to ensure patient transparency. As cannabis is often ingested, FDA food labeling standards provide a relevant model for consumer protection. Labeling irradiated or ozone-treated products aligns with existing cannabis transparency standards, like potency labeling, promoting fairness and informed choice.

LD 1567 protects consumers and patients by ensuring transparency about cannabis treatments. I urge the committee to pass this bill to uphold my right to know what I’m consuming.